curasonix has already been marketing the curason® Ultrasonic Wound Cleanser since October 2021, a unique instrument for the cleansing of infected wounds, open legs and other infected and poorly healing wounds. It is unsurpassed in price-performance ratio, meets all needs of customers, patients and commercially interested parties and is a fully approved medical device (CE certification).

 

With curason, we are making it possible for the first time to effectively clean infected wounds so that no patient has to suffer from non-healing wounds any longer.

 

In Germany, 1-2 million patients suffer from leg ulcers that do not heal properly because they are infected - this is a heavy burden for the patients both physically and psychologically with far-reaching consequences up to blood poisoning or amputation of the limb. Until now, there has been no adequate solution and existing wound cleansing procedures are inefficient, cannot be used on a mobile basis and thus do not reach the steadily growing number of patients, and this is where curasonix comes into play.

In terms of ease of use, the curason is similar to an electric toothbrush. It consists of a handset and a cleaning head with a brush structure. The cleaning heads are individually sterile-packed and can be used only once for hygienic reasons. By selling single-use cleaning heads, we generate stable recurring revenue. Each newly installed product thus contributes to the steady growth of our sales over the years via the continuous consumption of cleaning heads.

Product development and approval have already been fully completed, financed and the product is now ready for series production. More than 100 end customers are already using the curason and are enthusiastic about the product.

 

Top reasons for an investment

You are investing in an already scaling company with unparalleled growth potential in an almost unlimited market volume (EUR 7 billion p.a.).

• curasonix revolutionizes the wound cleansing market: For the foreseeable future, there is no competitive product to curason
• unrivalled value for money: the curason's acquisition costs are 3-10% and the running costs 10-50% of competing products
• Unbeaten in effectiveness: Conventional devices cannot simultaneously remove coarse and fine plaque painlessly, deeply break up the microscopic biofilm, and stimulate vascular growth in the process
• medically approved and marketed: already more than 100 users benefit from the incomparable effectiveness of curason
• unparalleled growth potential and return on investment opportunities: we see a global market potential of up to EUR 7 billion and a targeted revenue growth to EUR 36 million in 2027
• Successfully managed by an experienced team: More than 70 years of entrepreneurial know-how in the field of life science and medical technology (30 years of which alone in the field of wound treatment)

curasonix has been in existence since 2015 and has been ISO 13485 certified as a medical device developer and manufacturer since 2017. Since 2021, curason has been approved as a medical device and is already successfully sold in over 10 countries worldwide. The financing round serves to scale and increase production capacities to meet the rapidly growing demand.

 

The unique combination of the three principles for wound cleansing makes the curason, as the first and only hand-held instrument for the treatment of infected wounds, also unsurpassed in its effectiveness.

The three principles of curason wound cleansing:

1. mechanical removal of deposits
2. removal of bacteria by vibration and rinsing
3. deep-acting ultrasonic cavitation for combating biofilms

 

The flexible handset is the consistent implementation of market and customer needs in a revolutionary product. The cleaning heads of the curason are individually sterile-packaged and can be used only once. Accidental reuse is ruled out by a new type of software protection.

The curason is a hand-held ultrasonic wound cleanser for removing bacterial and wound coatings and cleaning infected open wounds. It consists essentially of two parts, a reusable handheld device and a disposable, attachable, sterile head for treatment-specific billing with recurring revenue. The innovative technology is protected from imitation by 15 patents worldwide.

With curason, we are for the first time enabling patients with open wounds to receive gentle, low-pain treatment that is otherwise often a painful and traumatic experience. The application is not only simple, but also safe and effective. More than 100 end customers are already using the curason and are convinced of its performance, including leading university hospitals worldwide.

 

The curason is also sustainable:

• 80% less water consumption compared to existing wound cleansing methods
• The base material of the curason head can be recycled and reused Energy savings due to fewer ambulance visits and patient transports
• Energy savings due to fewer ambulance visits and patient transports
• Use of a particularly energy-efficient sterilization process for the cleaning heads
• Savings in dressing materials, as a well-cleaned wound heals much faster and requires fewer dressing changes
• Less administration of antibiotics for infection control and thus avoidance of new, dreaded, antibiotic-resistant bacterial strains

The curason is easy to use, applicable not only by physicians but also by nurses, extremely effective, yet painless and inexpensive to purchase and maintain. It combines all the advantages of the well-known wound cleansing technologies (ultrasound, mechanical wound cleansing, vibration) in one unique product. There is extensive patent protection in 15 countries and there is no competitive product or alternative solution on the market.

The business model is based on the rental of the handset (HA) and the sale of the disposable cleaning heads (RK)

 

Revenue growth 2021 - 2027 based on recurring revenues

 

 

Distribution of sales according to revenue sources

The share of recurring revenues from sales of cleaning heads to the installed customer base and annual rental income is steadily increasing.

Therapists and providers of patients with infected wounds and wound healing disorders in Europe, North Africa, Asia, North America and South America. Approximately 35-70 million affected patients with infected wounds are under treatment worldwide.

 

Worldwide presence

 

Market size and market potential

Charts Market growth 2020 to 2027 (bars) incl. growth curasonix 2021 to 2027 in figures (sales and profit)

 

Market potential

At any given time, between 35 and 70 million patients with chronic or infected wounds are receiving medical or clinical treatment worldwide. With an average of 5 curason treatments per year per patient, the total market potential is 175 - 350 million curason applications annually, resulting in a potential market size of approximately 3.5 - 7.0 billion Euros annually.

Increase production to meet the ever-growing need and demand and thus sell according to the order situation. This requires capital for automation and for tools, as well as raw materials and adequate staff increases.

• Company certification (ISO 13485), 2017
• Completion of technical development, 2019
• EU approval (CE certification), 2021
• First sales in EU and MENA, 2021
• Expansion of dealer network in 22 countries, 2021
• Approval Thailand (Thai FDA), 2022
• Approval Brazil (ANVISA), 2022
• Positive feedback from customers (San Raphaele Ospedale, Akademie WKZ (D-A-CH), Uni Turin Mauriziano, Bumrungrad Hospital, Bangkok), University Ljubljana Dermatology and Surgery.

 

 

• Research cooperation with Danish Technological Institute, Aarhus and Fraunhofer IWU, Dresden

 

 

• State funding in 2020 from MBG Schleswig-Holstein (300,000 EUR) and IB-SH (250,000 EUR)